SIGA Technologies, Inc. (NASDAQ:SIGA – Get Free Report) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 4,100,000 shares, an increase of 28.5% from the February 13th total of 3,190,000 shares. Based on an average daily trading volume, of 444,200 shares, the short-interest ratio is currently 9.2 days. Currently, 10.1% of the company’s shares are sold short.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Principal Financial Group Inc. purchased a new stake in SIGA Technologies in the 3rd quarter valued at $149,000. Victory Capital Management Inc. raised its holdings in shares of SIGA Technologies by 5.8% in the third quarter. Victory Capital Management Inc. now owns 259,143 shares of the company’s stock valued at $1,749,000 after purchasing an additional 14,286 shares during the last quarter. Segall Bryant & Hamill LLC grew its position in SIGA Technologies by 1.8% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 325,136 shares of the company’s stock worth $2,195,000 after purchasing an additional 5,772 shares in the last quarter. Intech Investment Management LLC bought a new position in SIGA Technologies in the 3rd quarter valued at $120,000. Finally, Foundry Partners LLC bought a new position in shares of SIGA Technologies during the 3rd quarter valued at approximately $2,801,000. Institutional investors own 55.40% of the company’s stock.
SIGA Technologies Price Performance
Shares of SIGA traded up $0.08 during trading hours on Monday, hitting $5.66. 15,274 shares of the stock were exchanged, compared to its average volume of 826,257. The firm has a market capitalization of $404.33 million, a P/E ratio of 4.70 and a beta of 0.98. The business has a 50-day moving average of $5.98 and a 200-day moving average of $6.62. SIGA Technologies has a fifty-two week low of $5.16 and a fifty-two week high of $12.83.
SIGA Technologies Company Profile
SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Featured Articles
- Five stocks we like better than SIGA Technologies
- Differences Between Momentum Investing and Long Term Investing
- Super Micro’s International Presence Makes It a Winning Stock
- The How and Why of Investing in Gold Stocks
- Grocery Outlet Insider and Institutional Buyers Signal Bottom
- What is the Euro STOXX 50 Index?
- Consumers Are Cutting Back, But These 3 Stocks Will Stay Strong
Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.